TAmiRNA to indicate new microRNA functions at ASBMR Annual Meeting 2017 in Denver

Vienna, Austria:- Innovative biotech company TAmiRNA will present new scientific results on the biological functions and disease mechanism of microRNAs, potentially leading to applications as novel biomarkers and drug targets for bone diseases.

TAmiRNA will also be an exhibitor at the event at Booth 435, where a team led by CEO, Dr. Matthias Hackl, along with co-founder and scientific advisor, Dr. Johannes Grillari, will demonstrate the company’s innovative osteomiR™ test kits. The osteomiR™ kit enables rapid detection of microRNAs that could serve as novel biomarkers for early diagnosis and prognosis of fracture risk in post-menopausal osteoporosis.

Live demonstrations

Mrs. Ho Thi Thuy Oanh and Dr. Elisabeth Gadermaier from distribution partners Biomedica will help to demonstrate handling and use of the osteomiR™ qPCR Kit.

The TAmiRNA display will also feature the company’s recently introduced contract research services for RNA biomarker discovery and validation.

“We have built up a close relationship with the ASMBR annual meeting, having attended for the past five years and had TAmiRNA-related scientific projects repeatedly receiving Investigator Awards,” said Dr. Hackl.

“The meeting provides us a wonderful opportunity to present the latest scientific evidence on microRNA’s to an eminently professional and expert audience,” he added.

Preventative therapies

Dr. Grillari commented: “The latest results open up new possibilities of identifying high-risk subsets that qualify for preventive therapeutic treatment. New biomarker targets that give insights into disease mechanism of osteoporosis.”

“The osteomiR microRNA signature is intended to assess the risk of a first fracture in female patients of postmenopausal osteoporosis and type-2 diabetes. This information enables timely interventions and can help to avoid fractures.” said Dr. Grillari.

Prize

TAmiRNA will also participate in the ASBMR Exhibit Hall Raffle, donating as a prize a bound version of the book “Translating microRNAs to the clinic”, which reviews the possibilities of current methodological tools and experimental approaches used by leading translational researchers.

Moreover TAmiRNA together with Biomedica will organize a “roll the dice contest” for all ASBMR attendees in which they can win discount on all TAmiRNA and Biomedica products and services.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com

About ASBMR 2017

The American Society for Bone and Mineral Research is one of the world’s leading professional, scientific and medical organizations for bone and mineral researchers and clinicians and forms a highly-effective voice for advocacy and science policy for nearly 4,000 scientists and clinicians from 60 countries.

The society’s annual meeting attracts leading scientists, researchers and laboratories from around the globe to exchange latest scientific insights, connect with colleagues and learn about leading edge products and services.

The 2017 ASBMR meeting is a four-day event opening September 8 at the Colorado Convention Center in Denver. It will feature more than 100 presentation and discussion sessions, including hands-on workshops, plenary presentations and topical symposia.

The 2017 conference will also be webcast via Live Online, ASBMR’s virtual conference experience.

More information available at: www.asbmr.org/meetings/annualmeeting.aspx